Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Search by expertise, name or affiliation
Development of docetaxel in advanced non-small-cell lung cancer
Chandra P. Belani
, John Eckardt
Department of Medicine
Division of Hematology and Oncology
Penn State Cancer Institute
Cancer Institute, Next-Generation Therapies
Research output
:
Contribution to journal
›
Article
›
peer-review
23
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Development of docetaxel in advanced non-small-cell lung cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Docetaxel
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Cisplatin
30%
Paclitaxel
23%
Vinorelbine
23%
Doublet
15%
First-line Therapy
15%
Platinum Doublets
15%
Gemcitabine
15%
Taxanes
15%
Clinical Trials
7%
Binding Affinity
7%
Lung Cancer
7%
Mechanism of Action
7%
Phase II Study
7%
Breast Cancer
7%
Carboplatin
7%
Previously Treated
7%
Metastatic Non-small Cell Lung Cancer
7%
Tubulin
7%
Semi-synthetic
7%
Third Generation
7%
Standard of Care
7%
Chemotherapy Agents
7%
Degree of Activity
7%
Therapeutic Benefits
7%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Docetaxel
100%
Cisplatin
30%
Paclitaxel
23%
Vinorelbine
23%
Gemcitabine
15%
Taxane
15%
Breast Cancer
7%
Clinical Trial
7%
Carboplatin
7%
Lung Cancer
7%
Chemotherapy Agent
7%
Beta Tubulin
7%